Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Noven Pharmaceuticals, Inc.
WARNING LETTER
•Noven Pharmaceuticals, Inc.•July 2, 2007

Noven Pharmaceuticals, Inc. – FDA Warning Letter, Jul 2, 2007

Record Details

An FDA inspection of Noven Pharmaceuticals, Inc. from June to July 2007 revealed that their Daytrana® methylphenidate TD patches are adulterated under 21 U.S.C. § 351(a)(2)(B) due to non-conformity with cGMP regulations (21 CFR Part 211).

Key violations include: 1. **Failure to establish scientifically sound specifications (21 CFR § 211.160(b))**: A liner release force specification for Daytrana® patches was absent, despite historical data showing variability in peel force. The company failed to evaluate this data or justify the lack of a commercial product specification. FDA requested an explanation for not developing an "adequate database" since 2002 and further data evaluation. While Noven provided a new specification in October 2007, FDA requested rationale, data, and clarification on its relevance and incorporation into stability protocols. 2. **Failure to assure drug product quality throughout expiry (21 CFR § 211.137(a))**: Noven lacked data to assure acceptable release characteristics for the new [redacted] release liner over the 24-month expiry period, despite acknowledging age-related "tight release" and/or "adhesive transfer" issues. FDA questioned the scientific basis for the 24-month expiry given the lack of real-

Company
Noven Pharmaceuticals, Inc.
Inspection date
July 2, 2007
Product type
Drugs
Office
Florida District Office
People
  • Emma R. Singleton (District Director)
  • Brant M. Schroeder (Compliance Officer)
View Company Profile

ID · 13431909-56a4-4a42-95f0-771a92570fd5

Violation Codes4
21 U.S.C. 351(a)(2)(B)21 CFR 21121 CFR 211.160(b)21 CFR 211.137(a)

Full citation text and observation details available on the Dashboard.

Other documents for Noven Pharmaceuticals, Inc.
  • WARNING_LETTER - 2011-02-14February 14, 2011

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Noven Pharmaceuticals, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.